Conversely, the 18-kDa LOX propeptide was found to be an effective inhibitor of the more invasive phenotype of breast cancer cells driven by ERBB2 and has been suggested to improve treatment in this subtype of breast cancer [47]. This evidence concerns the gene LOX and breast cancer.